FDA science board supports criticism of agency's BPA stance
At an Oct. 31 meeting, the US Food and Drug Administration (FDA)'s full science board unanimously endorsed a subcommittee report that criticized the FDA's stance on bisphenol A (BPA).
At an Oct. 31 meeting, the US Food and Drug Administration (FDA)'s full science board unanimously endorsed a subcommittee report earlier last week that criticized the FDA's stance on bisphenol A (BPA).
As reported by Reuters, the subcomittee had stated that the evidence the FDA used to assess the safety of bisphenol A (BPA) in consumer products is inadequate. The subcommittee claimed that the FDA did not take into account government and university studies that questioned the safety of BPA when the agency released a draft assessment in September.
In the assessment, the FDA defended the position it took in May by stating that, based on the evidence it evaluated, the exposure to BPA in products such as baby bottles is safe. The FDA did add that there are ways consumers can limit their exposure to BPA.
Major congenital malformations not linked to first trimester tetracycline use
November 22nd 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
